Management of Superficial Thrombophlebitis

• Status: Completed
• Trial end date: 2011-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to test the hypothesis that Fragmin (dalteparin sodium) subcutaneously once daily for 7 days is more effective than Ibuprofen given orally three times daily for 7 days for the treatment of superficial thrombophlebitis (STP).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Oklahoma
• Collaborator: Pfizer
• Treatments: Dalteparin; Heparin, Low-Molecular-Weight; Ibuprofen; Tinzaparin

Criteria

Inclusion Criteria:

• Patients with confirmed upper or lower extremity superficial thrombophlebitis by ultrasound imaging

Exclusion Criteria:

• Active, clinically significant bleeding

• Known hypersensitivity to NSAIDS, heparin or derivatives

• Currently pregnant or < 1 week post-partum

• Acquired bleeding diathesis

• Known inherited bleeding disorder

• Renal failure

• Extremes of weight

• unable to return for repeat diagnostic testing or follow-up visit

• Concurrent deep-vein thrombosis